EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Oncogenic MTOR Signaling Axis Compensates BTK Inhibition in a Chronic Lymphocytic Leukemia Patient with Richter Transformation: A Case Report and Review of the Literature

Thomas Parigger, Stephan Drothler, Christian Scherhäufl, Franz Josef Gassner, Maria Schubert, Markus Steiner, Jan Philip Höpner, Alexandra Hödlmoser, Lena Schultheis, Aryunni Abu Bakar, Daniel Neureiter, Lisa Pleyer, Alexander Egle, Richard Greil, Roland Geisberger, Nadja Zaborsky

Acta Haematologica · 2024-02-24 · 147 (5) · 604-611

DOI: 10.1159/000537791 ↗
AbstractBibliografische Angaben

Abstract

Introduction: Targeting the B-cell receptor pathway via ibrutinib, a specific inhibitor of Bruton’s tyrosine kinase, has shown marked clinical efficacy in treatment of patients with chronic lymphocytic leukemia (CLL), thus becoming a preferred first line option independent of risk factors. However, acquired resistance to ibrutinib poses a major clinical problem and requires the development of novel treatment combinations to increase efficacy and counteract resistance development and clinical relapse rates. Case Presentation: In this study, we performed exome and transcriptome analyses of an ibrutinib resistant CLL patient in order to investigate genes and expression patterns associated with ibrutinib resistance. Here, we provide evidence that ibrutinib resistance can be attributed to aberrant mammalian target of rapamycin (MTOR) signaling. Conclusion: Thus, our study proposes that combined use of MTOR inhibitors with ibrutinib could be a possible option to overcome therapy resistance in ibrutinib treated patients.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →